Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00122317 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
A Phase 3 study of Paroxysmal Hemoglobinuria, Nocturnal, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 187
- Enrollment target
- 20
- Study locations
NCT00122317: Completed Phase 3 study of Paroxysmal Hemoglobinuria, Nocturnal, sponsored by Alexion Pharmaceuticals.
NCT00122317 is a Phase 3 study of Paroxysmal Hemoglobinuria, Nocturnal that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 187 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00122317, a Phase 3 study of Paroxysmal Hemoglobinuria, Nocturnal, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 187 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.
Conditions Studied
Interventions
- DRUG eculizumab
Study Locations (20)
Maryland
- Johns Hopkins University Medical Center - Baltimore
- National Heart, Lung, and Blood Institute, National Institutes of Health - Bethesda
New York
- NYU Clinical Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Other
- Royal Melbourne Hospital, Department of Clinical Haematology & Medical Oncology - Parkville
- Ucl St. Luc, Hematology Department - Brussels
California
- Stanford University Medical Center, Division of Hematology - Stanford
Connecticut
- Hartford Hospital, Cancer Clinical Research Office - Hartford
Florida
- Cleveland Clinic Florida, Department of Clinical Research - Weston
Indiana
- Indianapolis University Cancer Center - Indianapolis
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
What the finished NCT00122317 record still lists
NCT00122317 is an interventional study that assigns participants to a tested intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Paroxysmal Hemoglobinuria, Nocturnal appearing as the primary indexed condition, and to 1 intervention - of which eculizumab is the first listed.
NCT00122317 names 20 study sites across 17 states, led by Maryland, New York, Other.
Frequently Asked Questions
What is clinical trial NCT00122317 about?
NCT00122317 is a clinical study titled "Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)". The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.
What is the current status of trial NCT00122317?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 187 participants. The study started on 2005-05. Estimated completion is 2008-10.
What conditions does trial NCT00122317 study?
This clinical trial studies the following conditions: Paroxysmal Hemoglobinuria, Nocturnal.
What interventions are being tested in trial NCT00122317?
The interventions under investigation include: eculizumab (DRUG).
Who is sponsoring clinical trial NCT00122317?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00122317 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Hemoglobinuria, Nocturnal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00122317's enrollment target sits among peer trials
187 1410th of 2000 higher than 589 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia